{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:39Z","timestamp":1787786079452,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Netherlands Ministry of Health Welfare and Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018887","name":"Roche Netherlands BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtocrr.2025.100853","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:06:25Z","timestamp":1748225185000},"page":"100853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal Circulating Tumor DNA\u2013Guided Resistance Analysis During Second-Line Osimertinib Treatment"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-1930","authenticated-orcid":false,"given":"J.W. Tijmen","family":"van der Wel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"Jebbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrina","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.R.","family":"van Lindert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva E.","family":"van der Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne E.A.","family":"Kastelijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrit","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.W.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100853_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100853_bib2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib3","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/cncr.28964","article-title":"Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib","volume":"120","author":"Sorensen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00280-021-04230-4","article-title":"Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors","volume":"87","author":"Verheijen","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMp1508811","article-title":"The path to cancer --three strikes and You\u2019re out","volume":"373","author":"Vogelstein","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100853_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2025.100853_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.jtocrr.2025.100853_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature14971","article-title":"A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity","volume":"525","author":"Waclaw","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2025.100853_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib10","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jtho.2017.02.020","article-title":"Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer","volume":"12","author":"York","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib11","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.jtho.2018.07.012","article-title":"Combination of crizotinib and osimertinib or erlotinib might overcome MET-mediated resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma","volume":"13","author":"Giroux-Leprieur","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2020.06.003","article-title":"The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy","volume":"146","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.064","article-title":"LBA51 - analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.063","article-title":"LBA50 - mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.annonc.2023.02.012","article-title":"Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial","volume":"34","author":"Remon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib16","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.3390\/cancers15174231","article-title":"Monitoring of plasma EGFR mutations during osimertinib treatment for NSCLC patients with acquired T790M mutation","volume":"15","author":"Watanabe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100853_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2025.100853_bib18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1538-7445.AM2019-1381","article-title":"Abstract 1381: Technical validation of Roche AVENIO sequencing platform for liquid biopsies","volume":"79","author":"Vessies","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100853_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.21037\/tlcr.2017.08.03","article-title":"Molecular diagnostics of lung cancer in the clinic","volume":"6","author":"Sholl","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100853_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107972","article-title":"Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort","volume":"198","author":"van der Wel","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2017.05.005","article-title":"Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients","volume":"109","author":"Zhu","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtocrr.2025.100853_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2025.100853_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","article-title":"Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:13:54Z","timestamp":1757650434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666364325000700"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100853","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Circulating Tumor DNA\u2013Guided Resistance Analysis During Second-Line Osimertinib Treatment","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100853"}}